Ettinger, Neil
for the ISABELA 1 and 2 Investigators
2 papers on CoChat
Most cited papers
- Verified
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
Richeldi, L., Fernández Pérez, E. R., Costabel, U., Albera, C., Lederer, D. J., Flaherty, K. R., Ettinger, N., Perez, R., Scholand, M. B., Goldin, J., et al. (2020) · The Lancet Respiratory Medicine
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisConnective Tissue Growth Factor Research
Cited by 293
- Verified
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials
Maher, T. M., Ford, P., Brown, K. K., Costabel, U., Cottin, V., Danoff, S. K., Groenveld, I., Helmer, E., Jenkins, R. G., Milner, J., et al. (2023) · JAMA
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research
Cited by 148
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free